Inventor
TEPLYAKOV ALEXEY
US30 patents
⚠️ This page may combine multiple inventors who share the name “TEPLYAKOV ALEXEY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JANSSEN BIOTECH INC
20 patentsUS9102737B2Aug 11, 2015
Human anti-CD27 antibodies, methods and uses
JANSSEN BIOTECH INC36 citations96
US9522957B2Dec 20, 2016
Method of treating an inflammatory condition by administering toll-like 3 receptor antagonists
JANSSEN BIOTECH INC10 citations92
US9683046B2Jun 20, 2017
Nucleic acid molecules encoding anti-CD27 antibodies
JANSSEN BIOTECH INC7 citations83
US9481731B2Nov 1, 2016
Toll-like receptor 3 antagonists
JANSSEN BIOTECH INC9 citations83
US8999333B2Apr 7, 2015
Human tissue factor antibody and uses thereof
JANSSEN BIOTECH INC9 citations83
US8951525B2Feb 10, 2015
Human tissue factor antibody and uses thereof
JANSSEN BIOTECH INC11 citations83
US10301392B2May 28, 2019
Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies
JANSSEN BIOTECH INC3 citations72
US10669343B2Jun 2, 2020
Anti-CD154 antibodies and methods of using them
JANSSEN BIOTECH INC3 citations71
US11884722B2Jan 30, 2024
Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
JANSSEN BIOTECH INC1 citations69
US11414484B2Aug 16, 2022
Anti-CCL17 antibodies
JANSSEN BIOTECH INC1 citations68
US10844122B2Nov 24, 2020
Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
JANSSEN BIOTECH INC4 citations68
US10562948B2Feb 18, 2020
GM-CSF variants and methods of use
JANSSEN BIOTECH INC1 citations66
US9932404B2Apr 3, 2018
Methods of reducing clinical symptoms of viral infection by administering a toll-like receptor 3 antagonist
JANSSEN BIOTECH INC1 citations62
US11732050B2Aug 22, 2023
Neutralizing human anti-CD27 antibodies
JANSSEN BIOTECH INC0 citations61
US11421037B2Aug 23, 2022
Nucleic acids encoding anti-CD154 antibodies
JANSSEN BIOTECH INC0 citations61
US10544229B2Jan 28, 2020
Agonistic antibodies specifically binding CD40 and methods of use
JANSSEN BIOTECH INC1 citations60
US9944697B2Apr 17, 2018
Anti-CCL17 antibodies
JANSSEN BIOTECH INC1 citations58
US11208450B2Dec 28, 2021
GM-CSF variants and methods of use
JANSSEN BIOTECH INC0 citations56
US11787875B2Oct 17, 2023
Materials and methods for improved single chain variable fragments
JANSSEN BIOTECH INC1 citations54
US10689453B2Jun 23, 2020
Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies
JANSSEN BIOTECH INC0 citations51
CUNNINGHAM MARK
5 patentsUS9255153B2Feb 9, 2016
Polynucleotides encoding Toll-Like Receptor 3 antagonists
CUNNINGHAM MARK10 citations91
US9238693B2Jan 19, 2016
Method of treating asthma or reducing inflammatory cell lung inflammation by administering toll-like receptor 3 antibodies
CUNNINGHAM MARK3 citations82
US8540986B2Sep 24, 2013
Toll-like receptor 3 antagonists
CUNNINGHAM MARK2 citations61
US8460659B2Jun 11, 2013
Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
CUNNINGHAM MARK2 citations61
US8409567B2Apr 2, 2013
Toll-like receptor 3 antagonists
CUNNINGHAM MARK2 citations61
JANSSEN PHARMACEUTICA NV
3 patentsUS10562968B2Feb 18, 2020
Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
JANSSEN PHARMACEUTICA NV18 citations90
US9850310B2Dec 26, 2017
CD123 binding agents and uses thereof
JANSSEN PHARMACEUTICA NV23 citations90
US11685777B2Jun 27, 2023
Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
JANSSEN PHARMACEUTICA NV1 citations69